Clinical Trials

CLIN-60000-461: A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment

Link : TBD
Status : PENDING
Population : Osteosarcoma (AYA -residual OST (up to 30 yrs)
Description : Cabozantinib + best supportive care vs best supportive care only
PI : A. Gupta
Centers Opened : TBD
Phase : II
IIST/Pharma : Pharma